pediatrix(US:MD)2026-02-19 15:00Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [4] - The company expects 2026 adjusted EBITDA to be in the range of $280 million to $300 million, representing a 5% increase from 2025 [5] - Consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with same-unit pricing up just under 7% [6][9] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [6] - Variable practice incentive compensation and salary and benefits increased on a same-unit basis, while salary growth for Q4 was modestly below the previous six-quarter average of around 3% [7] Market Data and Key Metrics Changes - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [8] - The accounts receivable days sales outstanding (AR DSO) improved to 42.8 days, down almost 5 days year-over-year due to better cash collections [8] Company Strategy and Development Direction - The company is focusing on quality care and has introduced new programs to align physicians with the company's goals, including cash bonuses and stock price tracking elements [11] - There are plans to leverage telemedicine and expand in NICUs and maternal-fetal medicine, with a strong presence in OB hospital medicine [12][13] - The company aims to maintain its balance sheet strength while exploring growth opportunities without diluting its core pediatrics and obstetrics focus [13][14] Management's Comments on Operating Environment and Future Outlook - Management noted that the decrease in patient volume was primarily due to tough comparisons from the previous year [20] - The company is closely monitoring potential impacts from ACA subsidies and payer mix changes, but currently sees no significant changes [28][30] - The guidance for 2026 assumes steady metrics similar to those in 2025, with no significant changes expected [33] Other Important Information - The company has not factored in any contributions from M&A activity in 2026 but is open to opportunities that align with its core strengths [10][41] - The company anticipates a decline in G&A expenses for 2026, forecasting them to be in the range of $230 million to $240 million [9] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management expects flat volume and pricing for 2026, with no significant changes anticipated [18] Question: Reasons for negative patient volume year-over-year - The decrease in volume was attributed to tough comparisons from the previous year's fourth quarter [20] Question: Details on variable compensation expenses - Management indicated that alignment with physicians is a key driver, rather than smoothing effects [25] Question: Guidance on pricing and payer mix - Management expects pricing to remain steady, with some favorable payer mix observed in 2025 [30] Question: Insights on G&A cost reductions - Management noted a small expected decline in G&A expenses, with no specific factors driving this [36] Question: Share repurchase plans - Management anticipates a smaller amount of stock buyback compared to 2025 [38] Question: Growth opportunities and potential M&A - Management is exploring various growth avenues, including telemedicine and physical practices, while being cautious about M&A that could dilute core strengths [39][41]